How to Structure PTSD Pharmacotherapy in Operational Stress Injury Clinics
How should clinicians structure medication treatment for patients with chronic military-related posttraumatic stress disorder seen in operational stress injury clinics?
Patients treated in Canadian operational stress injury clinics commonly have chronic posttraumatic stress disorder, long prior treatment exposure, and psychiatric or medical comorbidity. In this setting, prescribing often starts from guideline-concordant antidepressant treatment but expands into symptom-targeted adjunctive therapy when insomnia, nightmares, hyperarousal, or comorbid symptoms persist.
-
Assess chronicity, prior treatment exposure, and comorbidity
Start by determining whether the patient resembles the high-complexity population described in the article: average PTSD chronicity was 8.15 years, 62.6% had received pharmacologic treatment for PTSD for 5 years or longer, and 78.3% had at least 1 comorbid mental health condition. Use these features to frame expectations, because the authors interpret frequent polypharmacy as a response to persistent symptom clusters and extensive prior treatment history rather than straightforward first-line treatment alone.
-
Use an SSRI or SNRI as the pharmacologic foundation when feasible
Build treatment around an SSRI or SNRI when using pharmacotherapy for PTSD, because antidepressants were the most commonly prescribed class and the authors describe SSRIs and SNRIs as central to treatment and broadly aligned with guideline-recommended first-line care. These agents were especially common among patients receiving fewer medications, indicating they often form the initial or core regimen even in specialized clinics.
-
Identify the dominant residual symptom clusters driving augmentation
If symptoms persist despite a first-line antidepressant approach, clarify which symptom clusters are still causing impairment. The article specifically describes adjunctive prescribing as targeting severe insomnia, nightmares, hyperarousal, acute anxiety, mood dysregulation, and comorbid conditions, rather than relying on one medication to address overall PTSD symptoms.
-
Add symptom-targeted adjunctive classes selectively
When residual symptoms warrant additional treatment, consider that real-world OSI prescribing commonly extended to hypnotics, antiadrenergics, antipsychotics, and sometimes benzodiazepines. In the study, low-dose trazodone used as a hypnotic, zopiclone, zolpidem, doxazosin, and quetiapine were among the most common PTSD-indicated medications, reflecting symptom-targeted management of sleep disturbance, nightmares, and related symptoms.
-
Weigh tolerability, interactions, and physical comorbidity explicitly
Before choosing or modifying medication, review factors that psychiatrists in the study consistently rated as important: positive prior experience with a specific medication, tolerability and avoidance of known side effects, potential interactions with current medications or substances, and comorbid physical conditions. These were more consistently influential than formulary or insurance considerations in the participating clinics.
-
Expect regimen complexity in refractory cases
Do not assume antidepressant monotherapy will remain sufficient in chronic operational trauma populations. The mean number of PTSD-indicated medications was 3.04 per patient, and the authors interpret the frequent use of 3 or more medications as an effort to manage persistent, multi-domain symptoms when first-line options alone are insufficient, poorly tolerated, or slow to act.
Clinical Considerations
- This article reports cross-sectional prescribing patterns and cannot establish which medication strategies caused better outcomes.
- The study did not capture the full clinical reasoning behind individual prescribing decisions when treatment diverged from guideline recommendations.
- The role of psychotherapy in shaping medication choices was not examined, even though concurrent psychotherapy may influence pharmacologic strategy.
- Findings reflect participating Canadian operational stress injury clinic sites and may not generalize to all PTSD treatment settings or all OSI clinics.
Bottom Line
In operational stress injury clinics, structure PTSD pharmacotherapy around an SSRI or SNRI foundation, then add symptom-targeted agents only in response to persistent insomnia, nightmares, hyperarousal, anxiety, or comorbidity in chronic, treatment-experienced patients.
